Reported about 9 hours ago
Aytu BioPharma has entered an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize Exxua, an extended-release antidepressant approved by the FDA for major depressive disorder (MDD) in adults. Aytu is committed to royalty and milestone payments tied to net sales, with plans to launch Exxua in the US market by late 2025, aiming to provide a vital treatment option for the 21 million Americans affected by MDD. Aytu's CEO emphasized the importance of Exxua in addressing the unmet needs of depression patients.
Source: YAHOO